| Bioactivity | Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 µM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups[1][2][3]. |
| Invitro | Nefopam (0.1-100 µM; 15 min) inhibits the uptake of 22Na in a concentration-dependent manner in SK-N-SH cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Nefopam (0-10 mg/kg; i.v.; single) protects mice against electroshock induced seizures[1].Nefopam (10, 30, 60 mg/kg; i.p.; single) shows a dose-dependent attenuation of mechanical allodynia and decreased neurokinin-1 receptor concentration in vincristine-induced peripheral neuropathy model[2]. Animal Model: |
| Name | Nefopam |
| CAS | 13669-70-0 |
| Formula | C17H19NO |
| Molar Mass | 253.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Verleye M, et al. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res. 2004 Jul 9;1013(2):249-55. [2]. Lee JY, et al. The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice. J Pain Res. 2020 Feb 7;13:323-329. [3]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. |